secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001140361-23-042505
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Phase 3 ARISE study meets primary endpoint; ARIKAYCE shows strong culture conversion in MAC lung disease
--------------------------------------------------------------------------------

- ARISE validated QOL-B respiratory domain as PRO tool; to be proposed as primary endpoint for ENCORE without modification.
- ARIKAYCE arm achieved 78.8% culture conversion at Month 7 vs 47.1% for comparator (p=0.0010).
- QOL-B respiratory score improvement trend: 12.24 vs 7.76 (p=0.1073); 43.8% of ARIKAYCE patients exceeded meaningful threshold.
- No new safety signals; discontinuation rate 22.9% for ARIKAYCE vs 7.8% for comparator.
- Insmed plans to explore accelerated filing for ARIKAYCE in newly infected MAC patients with global regulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123042505/0001140361-23-042505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123042505/brhc20058439_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-042505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer